Literature DB >> 20197388

Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma.

Elyssa M Rubin1, Yi Guo, Khoa Tu, Jun Xie, Xiaolin Zi, Bang H Hoang.   

Abstract

It has been reported that the progression of osteosarcoma was closely associated with the aberrant activation of canonical Wnt signaling. Wnt inhibitory factor-1 (WIF-1) is a secreted Wnt inhibitor whose role in human osteosarcoma remains unknown. In this study, WIF-1 expression in NHOst and osteosarcoma cell lines was determined by real-time reverse transcription-PCR, methylation-specific PCR, and Western blotting analysis. In addition, tissue array from patient samples was examined for WIF-1 expression by immunohistochemistry. Compared with normal human osteoblasts, WIF-1 mRNA and protein levels were significantly downregulated in several osteosarcoma cell lines. The downregulation of WIF-1 mRNA expression is associated with its promoter hypermethylation in these tested cell lines. Importantly, WIF-1 expression was also downregulated in 76% of examined osteosarcoma cases. These results suggest that the downregulation of WIF-1 expression plays a role in osteosarcoma progression. To further study the potential tumor suppressor function of WIF-1 in osteosarcoma, we established stable 143B cell lines overexpressing WIF-1. WIF-1 overexpression significantly decreased tumor growth rate in nude mice as examined by the s.c. injection of 143B cells stably transfected with WIF-1 and vector control. WIF-1 overexpression also markedly reduced the number of lung metastasis in vivo in an orthotopic mouse model of osteosarcoma. Together, these data suggest that WIF-1 exerts potent antiosteosarcoma effect in vivo in mouse models. Therefore, the reexpression of WIF-1 in WIF-1-deficient osteosarcoma represents a potential novel treatment and preventive strategy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20197388      PMCID: PMC2837364          DOI: 10.1158/1535-7163.MCT-09-0147

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  43 in total

1.  A new secreted protein that binds to Wnt proteins and inhibits their activities.

Authors:  J C Hsieh; L Kodjabachian; M L Rebbert; A Rattner; P M Smallwood; C H Samos; R Nusse; I B Dawid; J Nathans
Journal:  Nature       Date:  1999-04-01       Impact factor: 49.962

2.  Adenovirus-mediated overexpression of REIC/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-kinase.

Authors:  Fernando Abarzua; Masakiyo Sakaguchi; Mikiro Takaishi; Yasutomo Nasu; Kyouhei Kurose; Shin Ebara; Masahiro Miyazaki; Masayoshi Namba; Hiromi Kumon; Nam-ho Huh
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

3.  Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience.

Authors:  Valerie Mialou; Thierry Philip; Chantal Kalifa; David Perol; Jean-Claude Gentet; Perrine Marec-Berard; Helene Pacquement; Pascal Chastagner; Anne-Sophie Defaschelles; Olivier Hartmann
Journal:  Cancer       Date:  2005-09-01       Impact factor: 6.860

4.  An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis.

Authors:  Hue H Luu; Quan Kang; Jong Kyung Park; Weike Si; Qing Luo; Wei Jiang; Hong Yin; Anthony G Montag; Michael A Simon; Terrance D Peabody; Rex C Haydon; Carrie W Rinker-Schaeffer; Tong-Chuan He
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

5.  Overexpression of matrix metalloproteinase (MMP)-9 correlates with metastatic potency of spontaneous and 4-hydroxyaminoquinoline 1-oxide (4-HAQO)-induced transplantable osteosarcomas in rats.

Authors:  A Kido; M Tsutsumi; K Iki; M Takahama; T Tsujiuchi; T Morishita; S Tamai; Y Konishi
Journal:  Cancer Lett       Date:  1999-04-01       Impact factor: 8.679

6.  The extracellular matrix component WIF-1 is expressed during, and can modulate, retinal development.

Authors:  Dale D Hunter; Minlei Zhang; Jill W Ferguson; Manuel Koch; William J Brunken
Journal:  Mol Cell Neurosci       Date:  2004-12       Impact factor: 4.314

7.  Matrix metalloproteinase-9 (MMP-9) expression in childhood osseous osteosarcoma.

Authors:  B P Himelstein; N Asada; M R Carlton; M H Collins
Journal:  Med Pediatr Oncol       Date:  1998-12

8.  Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis.

Authors:  N M Marina; C B Pratt; B N Rao; S J Shema; W H Meyer
Journal:  Cancer       Date:  1992-12-01       Impact factor: 6.860

9.  Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study.

Authors:  M B Harris; P Gieser; A M Goorin; A Ayala; S J Shochat; W S Ferguson; T Holbrook; M P Link
Journal:  J Clin Oncol       Date:  1998-11       Impact factor: 44.544

10.  Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice.

Authors:  Maya Kansara; Michael Tsang; Laurent Kodjabachian; Natalie A Sims; Melanie K Trivett; Mathias Ehrich; Alexander Dobrovic; John Slavin; Peter F M Choong; Paul J Simmons; Igor B Dawid; David M Thomas
Journal:  J Clin Invest       Date:  2009-03-23       Impact factor: 14.808

View more
  63 in total

Review 1.  Emerging therapeutic opportunities for skeletal restoration.

Authors:  Masanobu Kawai; Ulrike I Mödder; Sundeep Khosla; Clifford J Rosen
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

2.  Wnt/β-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium.

Authors:  Eugenia C Pacheco-Pinedo; Amy C Durham; Kathleen M Stewart; Ashley M Goss; Min Min Lu; Francesco J Demayo; Edward E Morrisey
Journal:  J Clin Invest       Date:  2011-04-01       Impact factor: 14.808

3.  Evidence for the osteosarcoma stem cell.

Authors:  C Parker Gibbs; Padraic P Levings; Steven C Ghivizzani
Journal:  Curr Orthop Pract       Date:  2011-07

4.  Wnt signaling in bone formation and its therapeutic potential for bone diseases.

Authors:  Jeong Hwan Kim; Xing Liu; Jinhua Wang; Xiang Chen; Hongyu Zhang; Stephanie H Kim; Jing Cui; Ruidong Li; Wenwen Zhang; Yuhan Kong; Jiye Zhang; Wei Shui; Joseph Lamplot; Mary Rose Rogers; Chen Zhao; Ning Wang; Prashant Rajan; Justin Tomal; Joseph Statz; Ningning Wu; Hue H Luu; Rex C Haydon; Tong-Chuan He
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-02       Impact factor: 5.346

5.  Lung cancer transcriptomes refined with laser capture microdissection.

Authors:  Juan Lin; Gabrielle Marquardt; Nandita Mullapudi; Tao Wang; Weiguo Han; Miao Shi; Steven Keller; Changcheng Zhu; Joseph Locker; Simon D Spivack
Journal:  Am J Pathol       Date:  2014-08-14       Impact factor: 4.307

6.  MicroRNA-374a activates Wnt/β-catenin signaling to promote breast cancer metastasis.

Authors:  Junchao Cai; Hongyu Guan; Lishan Fang; Yi Yang; Xun Zhu; Jie Yuan; Jueheng Wu; Mengfeng Li
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

Review 7.  WNT signalling pathways as therapeutic targets in cancer.

Authors:  Jamie N Anastas; Randall T Moon
Journal:  Nat Rev Cancer       Date:  2013-01       Impact factor: 60.716

Review 8.  Deciphering signaling networks in osteosarcoma pathobiology.

Authors:  Christos Adamopoulos; Antonios N Gargalionis; Efthimia K Basdra; Athanasios G Papavassiliou
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-06

9.  The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition.

Authors:  David S Yee; Yaxiong Tang; Xuesen Li; Zhongbo Liu; Yi Guo; Samia Ghaffar; Peter McQueen; Dash Atreya; Jun Xie; Anne R Simoneau; Bang H Hoang; Xiaolin Zi
Journal:  Mol Cancer       Date:  2010-06-23       Impact factor: 27.401

10.  Common mechanism of pathogenesis in various types of metastatic osteosarcoma.

Authors:  Dongqi Wang; Zongrang Song; Zhan Wang
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.